Careers  |  Sign In  |  Register

Dr. Pavlick on the COLUMBUS Trial in Metastatic Melanoma

Anna C. Pavlick, DO, director of High Reliability Organization Initiatives and co-director of the Melanoma Program at NYU Langone Health’s Perlmutter Cancer Center, overviews next generation MEK and BRAF inhibitors used in the recently published phase 3 COLUMBUS trial for melanoma treatment. The COLUMBUS trial uses a combination of encorafenib and binimetinib, which was found superior when compared to vemurafenib or encorafenib alone.

Learn more by clicking here.